188 related articles for article (PubMed ID: 33706025)
1. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
2. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.
Hurtaud A; Donnadieu A; Escalup L; Cottu PH; Baffert S
Breast; 2016 Dec; 30():73-79. PubMed ID: 27639032
[TBL] [Abstract][Full Text] [Related]
4. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Lopes G; Glück S; Avancha K; Montero AJ
Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
[TBL] [Abstract][Full Text] [Related]
5. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Cortes J; Hudgens S; Twelves C; Perez EA; Awada A; Yelle L; McCutcheon S; Kaufman PA; Forsythe A; Velikova G
Breast Cancer Res Treat; 2015 Dec; 154(3):509-20. PubMed ID: 26567010
[TBL] [Abstract][Full Text] [Related]
7. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA; Awada A; Twelves C; Yelle L; Perez EA; Velikova G; Olivo MS; He Y; Dutcus CE; Cortes J
J Clin Oncol; 2015 Feb; 33(6):594-601. PubMed ID: 25605862
[TBL] [Abstract][Full Text] [Related]
8. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
9. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
10. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
[TBL] [Abstract][Full Text] [Related]
12. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Pouwels XGLV; Ramaekers BLT; Geurts SME; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; van Riel JMGH; Pepels MJ; Heijnen-Mommers J; Tjan-Heijnen VCG; de Boer M; Joore MA
Acta Oncol; 2020 Sep; 59(9):1123-1130. PubMed ID: 32544366
[No Abstract] [Full Text] [Related]
15. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Pivot X; Im SA; Guo M; Marmé F
Breast Cancer; 2018 May; 25(3):370-374. PubMed ID: 29302858
[TBL] [Abstract][Full Text] [Related]
16. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Kazmi S; Chatterjee D; Raju D; Hauser R; Kaufman PA
Breast Cancer Res Treat; 2020 Nov; 184(2):559-565. PubMed ID: 32808239
[TBL] [Abstract][Full Text] [Related]
17. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
[TBL] [Abstract][Full Text] [Related]
18. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
[TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]